Skip to main content Skip to navigation

Wellcome Translational Partnership

WWheader

What is the Warwick Wellcome Trust Translational Partnership?

Launched in 2020, the Warwick-Wellcome Translational Partnership aims to drive the translation of research into improvements in human health.

The partnership will accelerate the development of new preventative and therapeutic strategies to tackle ill-health locally, nationally and globally. It will help deliver lasting impact, whilst strengthening links with partners in both industry and clinical settings.

What will the Partnership deliver?

The Warwick-Wellcome Trust Translational Partnership will focus on investing in fellowships and projects aimed at exploiting emerging impact in the science of early life, tissue models of human disease and disease control and prevention. Two funding programmes are available to support people and new ideas, whilst developing a translational ecosystem across the University and local NHS trusts.

Translation Fellowships provide the opportunity for researchers to engage with translational research activities and take forward opportunities. Find out about the fellowships.

Translation and Innovation Grants provide project-focussed pump priming awards to overcome specific barriers and/or directed towards later stage projects that need support to move to the next technology readiness level. Find out about the grants.

Breaking Translational Barriers Awards, smaller awards of up to £10,000, are available to access bespoke external expertise and advice on the potential of the idea or technology and overcome well-defined barriers, for example engaging end users and networks, commissioning market research analyses and exploring routes to market to progress their research along the translational pipeline. The Breaking translational barriers awards will not fund Warwick staff time. 

What funding is currently available?

The second round for Translation and Innovation Grant applications is now closed.

We encourage applications for Breaking Translational Barriers Awards. Please contact Wellcome-Translation@warwick.ac.uk to discuss the Breaking translational barriers awards to access bespoke external expertise and advice.

Where can I find out more?

Find out about how to apply

Meet our Operational Leads

Andrew McAinsh
Professor Andrew McAinsh


Andrew Blanks
Dr Andrew Blanks

“We are excited to be developing a translational ecosystem here at Warwick and supporting outstanding projects and fellowships to drive improvements in human health"

News

Upcoming funding opportunity

Addressing limitations in manufacturing nucleic acid therapeutics

Funders: Medical Research Council (MRC), Engineering and Physical Sciences Research Council (EPSRC), Biotechnology and Biological Sciences Research Council (BBSRC), Innovate UK, UK Research and Innovation

Funding to set up a research consortium addressing challenges in the manufacture of nucleic acid therapeutics.

Current manufacture challenges include but are not limited to:

  • scale of production
  • product purity, stereochemistry and reproducibility
  • sustainable production
  • novel chemistries
  • synthesis efficiency
  • analytical oligonucleotide characterisation.

The consortium can include academic and industrial organisations in the UK and abroad. The lead organisation must be UK-based.

Consortium proposals should demonstrate how the research outputs could benefit the wider UK research and manufacturing community.

You are encouraged to explore opportunities to collaborate with the Nucleic Acid Therapy Accelerator (NATA) Hub, a new research centre in the UK.

Further details can be found here

https://www.ukri.org/opportunity/addressing-limitations-in-manufacturing-nucleic-acid-therapeutics/

Breaking Translational Barriers Awards available

Smaller awards of up to £10,000, are available to access bespoke external expertise and advice on the potential of the idea or technology and overcome well-defined barriers, for example engaging end-users and networks, commissioning market research analyses and exploring routes to market to progress their research along the translational pipeline.